“epigenetics” Archives

in
Entry Author Date Location
Omega Therapeutics Lands $85M to Tap Into “Control Room” of Biology 07/29/20 Boston
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More 09/27/19 National
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further 09/23/19 Boston
New VARI Initiative Aims to Understand How Metabolism Drives Disease 10/08/18 Detroit Ann Arbor
Lasker Awards Recognize Propofol Discovery, Women in Science Advocate & Others 09/11/18 National
Diagnostics Developer Nanopore Wins Agtech and Food Startup Showcase 04/30/18 Raleigh Durham
Constellation Reboots With Eye On Immuno-Oncology, Hires New CEO 05/25/17 Boston
Ex-Epizyme CEO’s New Startup, Fulcrum, Nabs $55M For Gene Control Drugs 07/19/16 Boston
With Tensha Purchase, Roche Interest in Bradner Startups Continues 01/11/16 Boston
With Drugs in Clinic, Constellation Nabs $55M For IPO Push 12/09/15 Boston
Constellation Pharma Plots IPO Run As Genentech Passes on Buyout Deal 08/24/15 Boston
Epizyme Buys Back Control of Cancer Drug From Eisai For up to $110M 03/12/15 Boston
East Coast Biotech Roundup: Alnylam, Stock Offerings, Curis, & More 01/23/15 Boston
Syros Raises $53M More To Push Gene-Control Drugs Into Human Trials 10/27/14 Boston
With $24M and Pharma Backing, Ex Epizyme Prez Aims to “Raze” Tumors 10/14/14 Boston
Six Takeaways from Boston’s Life Science Disruptors 10/13/14 Boston
Well-Traveled Rhodes Leaves Epizyme For Atlas Venture Partnership 09/29/14 Boston
Hear Epizyme, Sage, Zafgen Share Their Stories on Oct. 8 09/11/14 Boston
Rodin Moves From Seedling to Neurology Startup With $12.9M Series A 05/29/14 Boston
Forma Gets $225M More, And a Potential Buyout, From Celgene 04/01/14 Boston
Q&A: Behind Ignyta’s New Strategy on Cancer Drugs and Diagnostics 12/09/13 San Diego
Syndax Pockets $26.6M For Final Stage Push With Cancer Drug 08/27/13 Boston
Epizyme Execs Share the Secret to a Successful IPO: PowerBars 08/15/13 Boston
Atlas Startup, Rodin, Hopes to Rewire Neurons to Improve Memory 08/12/13 Boston
Trusting Your Partners: A Chat With Celgene’s George Golumbeski 07/11/13 New York
Epizyme Soars 50 Percent in IPO Debut 05/31/13 Boston
Epizyme Prices IPO at $15 Per Share, Begins Trading Friday 05/30/13 Boston
Forma Strikes $200M Deal With Celgene to Discover Cancer Drugs 04/29/13 Boston
Translating Nobel Science Into Novel Drugs 10/12/12 San Francisco
Genzyme, Epizyme, & Rib-X Among the Week’s Life Sciences Newsmakers 04/27/12 Boston
Page 1 of 2 next page »